What is the official website of FUJIFILM Pharmaceuticals U.S.A., Inc. ?

The official website of FUJIFILM Pharmaceuticals U.S.A., Inc. is https://www.fujifilmpharma.com/?utm_source=LinkedIn&utm_medium=company_page&utm_campaign=visit_website.

What is FUJIFILM Pharmaceuticals U.S.A., Inc.'s cybersecurity risk score?

FUJIFILM Pharmaceuticals U.S.A., Inc. has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has FUJIFILM Pharmaceuticals U.S.A., Inc. experienced?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has FUJIFILM Pharmaceuticals U.S.A., Inc. been affected by any supply chain cyber incidents ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have SOC 2 Type 1 certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not certified under SOC 2 Type 1.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have SOC 2 Type 2 certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. does not hold a SOC 2 Type 2 certification.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. comply with GDPR ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not listed as GDPR compliant.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have PCI DSS certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. does not currently maintain PCI DSS compliance.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. comply with HIPAA ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not compliant with HIPAA regulations.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have ISO 27001 certification ?

According to Rankiteo,FUJIFILM Pharmaceuticals U.S.A., Inc. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does FUJIFILM Pharmaceuticals U.S.A., Inc. operate in ?

FUJIFILM Pharmaceuticals U.S.A., Inc. operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc. employs approximately 8 people worldwide.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. own any subsidiaries ?

FUJIFILM Pharmaceuticals U.S.A., Inc. presently has no subsidiaries across any sectors.

How many LinkedIn followers does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc.'s official LinkedIn profile has approximately 1,355 followers.

What is the NAICS classification code for FUJIFILM Pharmaceuticals U.S.A., Inc. ?

FUJIFILM Pharmaceuticals U.S.A., Inc. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have a Crunchbase profile ?

No, FUJIFILM Pharmaceuticals U.S.A., Inc. does not have a profile on Crunchbase.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have a LinkedIn profile ?

Yes, FUJIFILM Pharmaceuticals U.S.A., Inc. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/fujifilm-pharma.

How many cybersecurity incidents has FUJIFILM Pharmaceuticals U.S.A., Inc. experienced ?

As of October 5, 2026, Rankiteo reports that FUJIFILM Pharmaceuticals U.S.A., Inc. has not experienced any cybersecurity incidents.

How many peer or competitor companies does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc. has an estimated 5,773 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FPUI

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

FUJIFILM Pharmaceuticals U.S.A., Inc. Vendor Cyber Rating & Cyber Score

fujifilmpharma.com

Add Your Compliance Badge

About FUJIFILM Pharmaceuticals U.S.A., Inc. Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost. FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILM’s global center for new drug development. Today we are conducting multiple clinical trials in conjunction with medical institutions and industry partners that share the same vision of contributing to human health. Harnessed through FUJIFILM’s long-standing operations in photographic films, we are also providing DDS technologies to help achieve higher efficacy of treatments with less side effects. DDS technologies are expected to ensure the delivery of the therapeutic agent to the targeted area, while

FPUI

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

FPUI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FPUI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incident Types FPUI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incident History - FPUI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

FUJIFILM Pharmaceuticals U.S.A., Inc. Subsidiaries

Parent Company

FPUI

Pharmaceutical Manufacturing

Website: https://www.fujifilmpharma.com/?utm_source=LinkedIn&utm_medium=company_page&utm_campaign=visit_website

Company Size: 2-10 employees

No subsidiary data available for this company.

Loading…

FUJIFILM Pharmaceuticals U.S.A., Inc. Similar Companies

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Loading…

NEWS

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 28, 2025 07:00 AM

Regeneron expands US manufacturing with $3B Fujifilm partnership

The company has started a supply partnership with Fujifilm Diosynth Biotechnologies valued at more than $3 billion.

Read Article

June 30, 2020 02:29 AM

Careers

Learn more about careers at Fujifilm, a globally recognized leader with more than 90 years of history in innovation and technology.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-105222

SUMMARY

The alexpechkarev/google-maps Laravel package through 12.16 disables TLS certificate verification by default because the bundled config sets ssl_verify_peer to FALSE, which is passed to CURLOPT_SSL_VERIFYPEER. On-path attackers can present any certificate to intercept Google Maps web-service requests, steal the API key from the query string, and tamper with responses.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

CVE-2026-105221

SUMMARY

The gist RubyGem before 6.1.0 contains an improper certificate validation vulnerability that allows on-path attackers to intercept HTTPS traffic because http_connection in lib/gist.rb sets VERIFY_NONE. Attackers can present any certificate to read or modify GitHub API traffic, stealing OAuth tokens and login credentials to read and modify the victim's gists.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

CVE-2026-105220

SUMMARY

Twine 2 desktop through 2.12.0 contains a cross-site scripting vulnerability in importStories() that executes markup from imported story files in the editor window. Attackers can craft a story file whose script calls the twineElectron openWithScratchFile IPC bridge to write and open a .bat file, executing code as the user.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.5

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-105167

SUMMARY

A vulnerability was determined in kishor-23 food-waste-management-system 411989e3ecb82895e53dca7865f72145f03d7d93/b3a70b2c492dc9904de5be1ad9389bd79b87f82c. The impacted element is an unknown function of the file admin/donate.php. Executing a manipulation of the argument location can lead to sql injection. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized. This product utilizes a rolling release system for continuous delivery, and as such, version information for affected or updated releases is not disclosed. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-105166

SUMMARY

A vulnerability was found in kishor-23 food-waste-management-system 411989e3ecb82895e53dca7865f72145f03d7d93/b3a70b2c492dc9904de5be1ad9389bd79b87f82c. The affected element is the function insert of the file fooddonateform.php of the component Food Donation Form. Performing a manipulation of the argument image-choice results in sql injection. The attack is possible to be carried out remotely. The exploit has been made public and could be used. This product adopts a rolling release strategy to maintain continuous delivery. Therefore, version details for affected or updated releases cannot be specified. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

FUJIFILM Pharmaceuticals U.S.A., Inc. Vendor Cyber Rating & Cyber Score

FPUI A.I CyberSecurity Scoring

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News & History

FPUI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for FPUI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types FPUI vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - FPUI (X = Date, Y = Severity)

FUJIFILM Pharmaceuticals U.S.A., Inc. Subsidiaries

Parent Company

FPUI

FUJIFILM Pharmaceuticals U.S.A., Inc. Similar Companies

Parexel

Alembic Pharmaceuticals Limited

Cipla

Intas Pharmaceuticals

Viatris

Bristol Myers Squibb

Torrent Pharmaceuticals Ltd

Novo Nordisk

MACLEODS PHARMACEUTICALS LTD.

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News

Regeneron expands US manufacturing with $3B Fujifilm partnership

Careers

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News & History

FPUI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for FPUI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types FPUI vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - FPUI (X = Date, Y = Severity)

FUJIFILM Pharmaceuticals U.S.A., Inc. Subsidiaries

Parent Company

FPUI

FUJIFILM Pharmaceuticals U.S.A., Inc. Similar Companies

Parexel

Alembic Pharmaceuticals Limited

Cipla

Intas Pharmaceuticals

Viatris

Bristol Myers Squibb

Torrent Pharmaceuticals Ltd

Novo Nordisk

MACLEODS PHARMACEUTICALS LTD.

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News

Regeneron expands US manufacturing with $3B Fujifilm partnership

Careers

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo